HRH3 and attention deficit-hyperactivity disorder: Likewise, in a randomized clinical study, ADHD-RS-IV score (primary efficacy end point of ADHD) of bavisant, a highly selective, wakefulness-promoting H3R antagonist, though displayed an improved trend, was not statistically significant compared with placebo in ADHD patients (Weisler et al., 2012).